Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
TROPION-PanTumor01
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
- NCT03401385 ↗
- Active, not recruiting
- Daiichi Sankyo Co., Ltd.
- Deep
We haven't built an HCP commentary report on TROPION-PanTumor01 (datopotamab deruxtecan in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TROPION-PanTumor01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 26 | |
| YouTube | 19 | |
| Podcasts | 13 |
The trial
ClinicalTrials.gov- Official title
- Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Hormone Receptor Positive Breast Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan (Dato-DXd); Steroid Containing Mouthwash; Non-Steroid Containing Mouthwash
- Arms
- Dose Escalation - All Participants · Experimental
- Dose Expansion - All Participants · Experimental
- Enrollment
- 890 (estimated)
- Primary outcomes
- Number of participants with dose-limiting toxicities
- Number of participants with adverse events (AEs)
- Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-Study
- Sponsor
- Daiichi Sankyo Co., Ltd. with Daiichi Sankyo, AstraZeneca
- Start
- Jan 31, 2018
- Primary completion
- Jan 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03401385 · updated Sep 1, 2026
Publications
linked from the registry- Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23. PubMed 38652877
- Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub 2024 Mar 11. PubMed 38502995
- Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol. 2023 Oct 10;41(29):4678-4687. doi: 10.1200/JCO.23.00059. Epub 2023 Jun 16. PubMed 37327461